Enveric Biosciences, Inc.
ENVB · NASDAQ
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | -0.00 | -0.00 | -0.00 |
| FCF Yield | -60.18% | -95,586.81% | -48.48% | -22.47% |
| EV / EBITDA | -0.12 | 2.04 | -0.15 | -0.51 |
| Quality | ||||
| ROIC | -115.30% | -55.84% | -199.72% | -52.72% |
| Gross Margin | 0.00% | 0.00% | 50.00% | 0.00% |
| Cash Conversion Ratio | 1.11 | 0.75 | 1.09 | 0.42 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | 20.97% | -82.35% | -41.47% | 67.91% |
| Safety | ||||
| Net Debt / EBITDA | 1.15 | 2.04 | 0.72 | 1.56 |
| Interest Coverage | -19,083.70 | 0.00 | 0.00 | 9,599.96 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | -4.78 |
| Cash Conversion Cycle | -2,343.35 | -743.33 | -275.91 | -630.41 |